Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Quarterly results
Appointed director
AMARIN CORP PLC (AMRN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/02/2023 8-K Quarterly results
07/20/2023 8-K Quarterly results
07/18/2023 8-K Results of Operations and Financial Condition, Cost Associated with Exit or Disposal Activities, Departure of Directors or Ce...
Docs: "Amarin Implements Organizational Restructuring to Strengthen the Company While Driving Patient Access to VASCEPA ® /VAZKEPA ® Globally",
"Amarin Appoints Patrick Holt as President and Chief Executive Officer"
05/03/2023 8-K Quarterly results
04/17/2023 8-K Quarterly results
03/31/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
03/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amarin Announces Board Departures"
03/02/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/01/2023 8-K Quarterly results
01/10/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "AMARIN PROVIDES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2022 REVENUE AND CASH POSITION AND PRIORITIES FOR 2023",
"Investor Deck dated January 2023"
01/10/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amarin Board of Directors Announces Appointment of Murray W. Stewart, DM FRCP."
01/03/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
12/07/2022 8-K Quarterly results
11/16/2022 8-K Quarterly results
10/27/2022 8-K Quarterly results
10/21/2022 8-K Quarterly results
08/19/2022 8-K Quarterly results
08/03/2022 8-K Quarterly results
Docs: "Amarin Reports Second Quarter 2022 Financial Results and Provides Business Update Company Received Final Positive Reimbursement Decision for VAZKEPA® by UK’s NICE in England & Wales Market Access Negotiations and Launch Preparations for VAZKEPA Underway Across Multiple European Markets Initiated Comprehensive Cost Reduction Plan in June to Address Market Dynamics in the U.S. with Expected Savings of $100 Million Over 12 Months* Plans On Track for Regulatory Filings for Approval of VASCEPA® in Several Additional Countries in 2022   Company to Host Conference Call Today at 8:00 a.m. ET DUBLIN, Ireland and BRIDGEWATER, N.J., August 3, 2022 --"
06/30/2022 8-K Quarterly results
06/06/2022 8-K Quarterly results
05/20/2022 8-K Quarterly results
05/04/2022 8-K Quarterly results
03/01/2022 8-K Quarterly results
01/10/2022 8-K Appointed a new director
Docs: "Amarin Provides Preliminary 2021 Revenue and Outlook for 2022 DUBLIN, Ireland and BRIDGEWATER, N.J., January 10, 2022 -- Amarin Corporation plc today provided a business update, including preliminary unaudited full-year 2021 revenue results. Amarin plans to discuss these results and expectations with investors in connection with the 40th Annual J.P. Morgan Healthcare Conference at which Amarin is scheduled to present virtually on Tuesday, January 11, 2022, at 8:15 am Eastern time. Preliminary 2021 Financial Results Revenue Levels: Full-year 2021 total net revenue, subject to audit, are estimated to be approximately $580 million, despite continued impact of global COVID-19 pandemic and generic competition in the United States. Fourth quarter 2021 total revenue is estimated to be approximate...",
"7 US CVD BURDEN EUROPE CVD BURDEN INTERNATIONAL CVD BURDEN"
11/03/2021 8-K Quarterly results
Docs: "Amarin Reports Third Quarter 2021 Financial Results and Provides Business Update Launched VAZKEPA in Germany with Multiple European Country Launches Expected in 2022 Introduced New Go-to-Market Strategy in U.S. to Enhance Awareness and Drive Demand for VASCEPA® Plans for Regulatory Filings and Approvals of VASCEPA in Several Additional Countries in 2022 Company to Host Conference Call Today at 7:30 a.m. ET"
09/27/2021 8-K Quarterly results
08/05/2021 8-K Quarterly results
06/15/2021 8-K Quarterly results
04/29/2021 8-K Quarterly results
04/12/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
01/29/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amarin Corporation plc Executive Severance and Change of Control Plan",
"Amarin Corporation plc Executive Severance and Change of Control Plan"
01/07/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "Amarin Reports Third Quarter 2020 Financial Results and Provides Business Update Total Revenue Increased 39% in Third Quarter 2020 and 56% in First Nine Months of 2020 Compared to Same Periods of 2019 Despite COVID-19 Headwinds"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy